文献速递慢性肾脏病血液净化与透析肾移植

综述:慢性肾脏病患者对SARS-CoV-2疫苗的早期免疫反应

Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD.
PubMed 文献 · Kidney Int Rep · 2021-07-06

该综述综合35项研究(28篇发表,7篇预印本),评估慢性肾脏病(CKD)患者接种SARS-CoV-2疫苗后的早期免疫反应。透析患者接种两剂mRNA疫苗后抗体阳性率为70%-96%,移植受者仅3%-59%产生可检测的体液或细胞反应;少数病例报告疫苗接种后肾炎复发或新发及急性移植排斥,提示需持续监测。

要点

  • 透析患者两剂mRNA疫苗后抗体阳性率70%-96%,一剂后仅18%-53%。
  • 移植受者两剂mRNA疫苗后仅3%-59%产生可检测的体液或细胞反应。
  • 疫苗接种后偶有肾炎复发或新发及急性移植排斥报告,需持续监测。

核心结论

  • 透析和移植患者对SARS-CoV-2疫苗的免疫反应差异大,移植受者反应率尤其低。
  • 疫苗接种后少数肾炎复发或新发及急性移植排斥病例提示需持续监测。

研究设计与样本

  • 综述35项研究(28篇发表,7篇预印本),样本量23至1140例,随访接种后1周至1个月。

主要发现

  • 透析患者接种一剂mRNA疫苗后抗体阳性率18%-53%,两剂后70%-96%。
  • 移植受者接种两剂mRNA疫苗后3%-59%产生可检测的体液或细胞反应。
  • 疫苗接种后有少数肾炎复发或新发及急性移植排斥病例报告。

关键数值与推荐

  • 透析患者两剂mRNA疫苗后抗体阳性率70%-96%,一剂后18%-53%。
  • 移植受者两剂mRNA疫苗后体液或细胞反应率3%-59%。

临床怎么用

  • 对移植受者和免疫反应不佳者,应考虑替代疫苗接种平台和策略。
  • 对自身免疫病和移植受者需严格监测长期不良反应。

局限性

  • 纳入研究样本量范围宽(23-1140例),随访仅1周至1个月。
  • 需更多研究评估这些人群SARS-CoV-2疫苗的真实有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The effects of the coronavirus disease-2019 (COVID-19) pandemic, particularly among those with chronic kidney disease (CKD), who commonly have defects in humoral and cellular immunity, and the efficacy of vaccinations against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are uncertain. To inform public health and clinical practice, we synthesized published studies and preprints evaluating surrogate measures of immunity after SARS-CoV-2 vaccination in patients with CKD, including those receiving dialysis or with a kidney transplant. We found 35 studies (28 published, 7 preprints), with sample sizes ranging from 23 to 1140 participants and follow-up ranging from 1 week to 1 month after vaccination. Seventeen of these studies enrolled a control group. In the 22 studies of patients receiving dialysis, the development of antibodies was observed in 18% to 53% after 1 dose and in 70% to 96% after 2 doses of mRNA vaccine. In the 14 studies of transplant recipients, 3% to 59% mounted detectable humoral or cellular responses after 2 doses of mRNA vaccine. After vaccination, there were a few reported cases of relapse or de novo glomerulonephritis, and acute transplant rejection, suggesting a need for ongoing surveillance. Studies are needed to better evaluate the effectiveness of SARS-CoV-2 vaccination in these populations. Rigorous surveillance is necessary for detection of long-term adverse effects in patients with autoimmune disease and transplant recipients. For transplant recipients and those with suboptimal immune responses, alternate vaccination platforms and strategies should be considered. As additional data arise, the NephJC COVID-19 page will continue to be updated (http://www.nephjc.com/news/covid-vaccine).

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Carr EJ, Kronbichler A, Graham-Brown M, et al. Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD. Kidney Int Rep. 2021. PMID: 34250319. doi:10.1016/j.ekir.2021.06.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。